---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-069473"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T04:54:26.677933+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem shows 45% ORR in LGSOC at ASCO; plans accelerated filing

## Summary
- Updated RAMP 201 Part A: confirmed ORR 45% in recurrent LGSOC; 86% tumor shrinkage.
- FDA Breakthrough Therapy for avutometinib + defactinib; accelerated approval filing planned.
- Cash $111M as of Q1 2023; up to $150M credit facility; up to $95M milestones from Secura Bio.
- Avutometinib shows best-in-class potential; expanding into NSCLC, pancreatic, CRC trials.
- Confirmatory trial for LGSOC initiation expected in H2 2023; multiple readouts in 2023.

## SEC filing metadata
- accession: 0001104659-23-069473
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465923069473/0001104659-23-069473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465923069473/tm2318212d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-069473
- JSON: https://secwatch.observer/filing/0001104659-23-069473.json
- Plain text: https://secwatch.observer/filing/0001104659-23-069473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.